ACIU AC Immune SA - Fundamental Analysis
BEARISH
Sign in to save
Save this symbol to a watchlist or track a position.
ACIU Stock | Fundamental Analysis & Investment Insights
NASDAQ
Healthcare
Biotechnology
Current Price
Live
$2.99
Analyst Target
$9.23
+208.8%
Upside
52W High
$4.0
52W Low
$1.43
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Feb 14, 2026
Market cap
$300.79M
P/E
N/A
ROE
-74.6%
Profit margin
N/A
Debt/Equity
0.07
Dividend yield
N/A
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
85%
Analysis Accuracy
ACIU's deterministic health scores signal severe financial distress: a Piotroski F-Score of 1/9 indicates extreme weakness in operational and financial health, while the absence of an Altman Z-Score raises bankruptcy risk concerns. The company exhibits catastrophic profitability metrics, including a -1671.88% operating margin and -74.63% ROE, alongside a 96.3% YoY revenue decline. Despite a strong analyst consensus of 'strong_buy' and a target price of $9.23, the stock trades at a premium valuation (Price/Sales of 68.80) with no earnings or cash flow support. Insider sentiment is neutral, and technical trends are bearish, reinforcing caution despite short-term price recovery.
Key Strengths
Analyst consensus remains strongly positive with a 'strong_buy' rating from 4 analysts
Recent quarterly earnings have shown signs of improvement in EPS surprise (e.g., +125.9% in Q4 2024)
Low debt/equity ratio of 0.07 suggests minimal leverage risk
Current and quick ratios above 1.0 indicate short-term liquidity adequacy
Significant 6-month price appreciation (+40.4%) suggests short-term market optimism
Key Risks
Piotroski F-Score of 1/9 indicates severe financial distress and operational failure
Negative and deteriorating profitability: -1671.88% operating margin, -74.63% ROE
96.3% YoY revenue decline signals core business contraction
No operating cash flow or free cash flow data available, indicating no cash generation
Price/Sales of 68.80 is extremely high for a company with no earnings or growth
No Graham Number or intrinsic value estimate available, making valuation speculative
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
21
Weak
20
40
30
15
0
AI Verdict
Weak
Key drivers: Extremely low Piotroski F-Score (1/9), Negative and deteriorating profitability, Massive revenue contraction, No cash flow generation, Premium valuation without earnings support
Confidence
85%
Value
20/100
Ref P/E, PEG, Graham Number
Positives
- Low debt/equity ratio (0.07) reduces financial risk
Watchpoints
- Price/Sales of 68.80 is extremely high for a non-profitable company
- No Graham Number or intrinsic value estimate available
- Forward P/E of -4.03 indicates no earnings support
- No cash flow metrics to support valuation
Future
40/100
Ref Growth rates
Positives
- Recent quarterly EPS surprises have improved (e.g., +125.9% in Q4 2024)
- Most recent Q/Q EPS growth is +23.8%
- Analyst target price of $9.23 implies strong growth expectations
Watchpoints
- 96.3% YoY revenue decline indicates business contraction
- Year-over-year EPS growth of -420.0% reflects deep deterioration
- No forward earnings or growth guidance available
Past
30/100
Ref Historical trends
Positives
- Some quarters have beaten estimates (e.g., Q4 2024: +125.9% surprise)
- Historical EPS trends show occasional improvement
Watchpoints
- Persistent negative earnings across 25 quarters
- Average earnings surprise of -4.41% over last 4 quarters
- Multiple quarters with massive negative surprises (e.g., -193.5%)
Health
15/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Current ratio (1.16) and quick ratio (1.12) indicate short-term liquidity
- Debt/Equity of 0.07 is very low
Watchpoints
- Piotroski F-Score of 1/9 is extremely low, indicating severe financial distress
- No Altman Z-Score available, but the financial profile suggests distress risk
- Negative ROE (-74.63%) and ROA (-21.96%) reflect poor capital efficiency
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend yield or payout ratio
- Dividend strength is 0/100
- Company is not generating profits to support dividends
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$2.99
Analyst Target
$9.23
Upside/Downside
+208.8%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ACIU and closest competitors.
Updated 2026-02-13
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ACIU
AC Immune SA
Primary
|
-62.2% | +29.4% | +11.6% | +40.4% | -18.5% | -4.8% |
|
AMRN
Amarin Corporation plc
Peer
|
-91.1% | -66.3% | +29.4% | -1.6% | +5.1% | -1.1% |
|
ACRS
Aclaris Therapeutics, Inc.
Peer
|
-86.7% | -75.9% | +45.0% | +70.6% | +16.4% | -10.6% |
|
AKBA
Akebia Therapeutics, Inc.
Peer
|
-63.3% | +88.4% | -43.1% | -61.8% | -20.0% | 0.0% |
|
BNR
Burning Rock Biotech Limited
Peer
|
-89.9% | +6.9% | +414.2% | +415.7% | +65.3% | +9.6% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-4.03
PEG Ratio
N/A
P/B Ratio
3.72
P/S Ratio
68.8
EV/Revenue
45.26
EV/EBITDA
-2.76
Market Cap
$300.79M
Profitability
Profit margins and return metrics
Profit Margin
N/A
Operating Margin
-1671.88%
Gross Margin
N/A
ROE
-74.63%
ROA
-21.96%
Growth
Revenue and earnings growth rates
Revenue Growth
-96.3%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.07
Low debt
Current Ratio
1.16
Good
Quick Ratio
1.12
Good
Cash/Share
$1.07
Quarterly Earnings History
EPS performance vs analyst estimates
2026-03-12
$N/A
2025-11-04
$-0.16
+7.8% surprise
2025-08-05
$-0.21
-29.2% surprise
2025-04-30
$-0.19
+8.2% surprise
Healthcare Sector Comparison
Comparing ACIU against 146 companies in the Healthcare sector
(10 bullish, 60 neutral, 76 bearish)
Return on Equity (ROE)
-74.63%
This Stock
vs
-56.84%
Sector Avg
+31.3%
(Excellent)
Debt to Equity
0.07
This Stock
vs
2.68
Sector Avg
-97.2%
(Less Debt)
Revenue Growth
-96.3%
This Stock
vs
61.93%
Sector Avg
-255.5%
(Slower)
Current Ratio
1.16
This Stock
vs
3.47
Sector Avg
-66.6%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ACIU
AC Immune SA
|
BEARISH | $300.79M | - | -74.6% | -% | $2.99 | |
|
AMRN
Amarin Corporation plc
|
BEARISH | $306.69M | - | -17.4% | -38.0% | $14.75 | |
|
ACRS
Aclaris Therapeutics, Inc.
|
BEARISH | $345.62M | - | -113.2% | -% | $3.19 | |
|
AKBA
Akebia Therapeutics, Inc.
|
NEUTRAL | $360.9M | - | -% | -7.1% | $1.36 | |
|
BNR
Burning Rock Biotech Limited
|
BEARISH | $377.58M | - | -20.2% | -22.5% | $35.07 |
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
4 analysts
BTIG
2025-11-04
Buy
Buy
BTIG
2025-09-08
Buy
Buy
Past News Coverage
Recent headlines mentioning ACIU from our newsroom.
Newest → oldest
No matching news yet.